Who is sponsoring NCT01132248?

NCT01132248 is sponsored by Albert Schweitzer Hospital.

What condition does NCT01132248 study?

NCT01132248 studies Urinary Schistosomiasis.

What drugs are being tested in NCT01132248?

Interventions: Mefloquine, S/P.

What is the status of NCT01132248?

NCT01132248 is currently COMPLETED.

Last reviewed 2013-01-23 · How we verify

Activity of Mefloquine Against Urinary Schistosomiasis

NCT01132248 Phase 2 COMPLETED

Urinary schistosomiasis is a debilitating disease in Central Africa and pregnant women are frequently suffering from this condition. Mefloquine is currently investigated as preventive treatment against malaria in pregnancy and mefloquine is also known to exert activity against schistosomiasis. The investigators want to test the hypothesis whether mefloquine may active against urinary schistosomiasis when used as preventive treatment against malaria in pregnancy.

Details

Lead sponsor	Albert Schweitzer Hospital
Phase	Phase 2
Status	COMPLETED
Enrolment	65
Start date	2010-05
Completion	2012-12

Conditions

Urinary Schistosomiasis

Interventions

Mefloquine
S/P

Primary outcomes

Reduction of egg excretion — 6 weeks after second IPTp
Mefloquine reduces egg excretion of Schistosoma haematobium by 50% compared to sulfadoxine/pyrimethamine (S/P) treatment when given as IPTp

Countries

Gabon